ImageneBio (IMA)
NASDAQ:IMA
IMA Stock Chart & Stats
$5.05
--
Market closed
$5.05
--
Day’s Range― - ―
52-Week Range$3.94 - $18.01
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$56.48M
Enterprise Value$31.51M
Total Cash (Recent Filing)$75.78M
Total Debt (Recent Filing)$9.99M
Price to Earnings (P/E)―
Beta0.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,654,281
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.25
Price to Sales (P/S)42.01
P/FCF Ratio-0.70
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.29
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$2.00Price Target Upside-60.40% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageLow debt-to-equity reduces immediate financial distress risk and preserves flexibility for a pre-commercial biotech. With limited leverage, the company can prioritize R&D and strategic options without high interest burdens, improving resilience during prolonged development timelines.
Improving Cash Burn TrendA meaningful reduction in cash burn rate suggests management has begun to control costs or optimize spending. Sustained lower burn stabilizes runway and reduces near-term financing pressure, allowing more time to advance clinical programs and pursue partnerships or non-dilutive funding.
Experienced Finance Leadership ContinuityPromoting a seasoned finance executive with biotech experience signals governance continuity and stronger financial stewardship. Improved finance leadership can enhance cash planning, reporting discipline, and credibility with investors and partners during fundraising or collaboration negotiations.
Bears Say
Revenue Declined To ZeroFalling to zero reported revenue indicates the company is fully pre-commercial or lacks recurring licensing income, increasing reliance on external financing. Without product cash flows, long-term sustainability depends on successful trials or partnerships, intensifying execution risk.
Persistent Negative Free Cash FlowConsistent negative operating and free cash flow means the business cannot self-fund R&D or operations. Ongoing cash burn elevates dilution and financing risk, constrains strategic flexibility, and forces management to prioritize short-term liquidity over longer-term program investment.
Eroding Equity BaseMaterial decline in shareholders' equity reflects cumulative losses and a shrinking capital buffer. A reduced equity base weakens absorption of future losses, may limit access to credit, and increases the probability of dilutive capital raises that can impair long-term shareholder value.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $3.94 and its highest was $18.01 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $56.48M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
Currently, no data Available
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Overvalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 10,654,281 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImageneBio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (-60.40% Downside)
$2.00 (-60.40% Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
-33.05%
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Company Description
ImageneBio
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
IMA Stock 12 Month Forecast
Average Price Target
$2.00
▼(-60.40% Downside)
Technical Analysis
Ownership Overview
32.92% Insiders
2.76% Mutual Funds
37.84% Other Institutional Investors
23.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---